Heiblig M, Gross Z, Belhabri A, Tauveron-Jalenques U, et al. Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry. Leukemia 2026;40:2191-2201.
PMID: 42469476